Skip to main content
OpenTrials
Completed

NCT Number: NCT04821336

Cholesterol Metabolites Analysis in Human Thyroid and Iodine Resistance

The study team previously shown that a cholesterol metabolite, dendrogenin A (DDA) differentiates anaplastic thyroid cancer cell lines and that its mRNA expression is diminished in human radioiodine refractory thyroid cancer samples. The team aim to quantify via mass spectrometry and immunohistochemistry DDA and other cholesterol metabolites in thyroid cancer versus healthy thyroid tissue human samples.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Thyroid Cancer Endocrine Gland Neoplasms Endocrine System Diseases Head and Neck Neoplasms Neoplasms Neoplasms by Site Thyroid Diseases Thyroid Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut Claudius regaud IUCT Oncopole

Toulouse, 31059, France

About this study

Retrospective study to analyze tissue samples of patients after thyroid surgery at Claudius Regaud Institute Toulouse, France, for thyroid cancer or thyroid aggressive lymphoma or benign thyroid pathology or other head&neck pathology necessitating total thyroidectomy despite normal thyroid.

Analysis focused on cholesterol metabolites quatification by mass spectrometry in liquid and gas phase.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who have undergone surgery at Institut Claudius Regaud for thyroid or laryngeal cancer confirmed by histology.
  • Patients who have consented before surgery, for the use of participants samples for future researches.

Exclusion criteria

  • None

Treatment and study plan

Metabolites dosage

Other

On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand.

The investigators will compare the rate of deregulation between sane and malignant ones.

Primary outcomes

  1. Rate of dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) in thyroid tissue (healthy or malignant)

    Time frame: 12 months after the beginning of the study

    The measurement expressed in ng / g of thyroid tissue

Secondary outcomes

  1. Presence of enzymes involved in dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) production

    Time frame: 12 months after the beginning of the study

    intensity of signal in Liquid Chromatography-Mass Spectrometry

  2. Number of enzymes involved in denrognenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) production

    Time frame: 12 months after the beginning of the study

    Quantify by immunohistochemistry

Sponsors and collaborators

Lead sponsor

Institut Claudius Regaud

Other

Collaborators

  • Cancer Research Center of Toulouse

Registry information

Official study title

Cholesterol Metabolites (Dendrogenin A or DDA, 6-oxo-cholestane-3β,5α-diol or OCDO,...) Quantification in Malignant Versus Normal Human Thyroid Tissue Refractory to Iodine

Acronym: OXYTHYR

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Mar 29, 2021
Registry last updated
May 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.